| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025 |
| 30 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +6 more
Form of Amended and Restated Limited Liability Company Agreement of the Surviving Company |
| 01 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) The purpose of this 2026 Equity Incentive Plan (the “Plan”) is to encourage key service providers of Pelthos Therapeutics Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by ... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 |
| 13 Aug 2026 |
8-K: Non-Reliance on Previously Issued Financial Statements
On August 12, 2026, the audit committee of our board of directors (the “Audit Committee”), in consultation with management, concluded that because of a misapplication of Accounting Standards Codification (“ASC”) 820, Fair Value Measureme... |
| 28 May 2026 |
8-K: Regulation FD Disclosure
1 Jefferies Global Healthcare Conference J U N E 4 , 2 0 2 6 Exhibit 99.2 |
| 21 May 2026 |
8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation
THIS SEPARATION AND RELEASE AGREEMENT (this “Agreement”) is made by and between Pelthos Therapeutics Inc. (the “Company”) and Francis Knuettel II (“Employee”). Each of the Company and Employee may be referred to herein as a “Party,” or c... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 |
| 14 Apr 2026 |
8-K: Regulation FD Disclosure
2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Wo... |
| 10 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Executive Employment Agreement (this “Agreement”) is made as of April 10, 2026, by and between Pelthos Therapeutics, Inc., a Nevada Corporation, (the “Company”), and John M. Gay (the “Executive”). |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including lic... |
| 13 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
The Lender, Collateral Agent and Co-Borrowers hereby agree as follows: |
| 12 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Wo... |
| 02 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Asset Purchase Agreement (this “Agreement”) is entered into as of this December 23, 2025, by and between Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation with a principal office at Level 17, 40 City Rd, Southbank, Victor... |
| 23 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Seasoned executive brings four decades of finance, capital markets, and life sciences experience |
| 17 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 17, 2025, Pelthos Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the three proposals that were voted on at the Annual Meeting and the stockholder vot... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Conference call scheduled for November 13, 2025 at 8:00am ET |
| 07 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as November 6, 2025, is by and among Pelthos Therapeutics Inc., a Nevada corporation with offices located at 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 (the “Company”... |
| 14 Oct 2025 |
8-K: Regulation FD Disclosure
Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Word... |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure
Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Word... |
Loading...